Kataoka Hiroshi, Ueno Satoshi
Department of Neurology, Nara Medical University, Kashihara, Nara, Japan.
Clin Neuropharmacol. 2011 Jan-Feb;34(1):48-9. doi: 10.1097/WNF.0b013e318204d35c.
The antiviral agent amantadine has been used to manage Parkinson's disease or levodopa-induced dyskinesias for nearly 5 decades. Amantadine is often associated with hallucinations as an adverse effect, but a long-term study reported no serious motor complications. We describe an unusual patient who had Parkinson's disease with dropped head syndrome (DHS) caused by amantadine. When the patient, who had DHS while receiving only 2 kinds of antiparkinsonian drugs, was rechallenged with amantadine, DHS developed, accompanied by increased muscle tone in the neck muscles on surface electromyogram. The DHS resolved after the withdrawal of amantadine. Moreover, an intravenous infusion of levodopa did not alter the DHS. These findings collectively suggest that the DHS in our patient was most likely caused directly by amantadine. Our findings suggest that amantadine may carry the risk of augmenting dystonic syndrome in humans.
抗病毒药物金刚烷胺用于治疗帕金森病或左旋多巴引起的运动障碍已有近50年。金刚烷胺常伴有幻觉这一不良反应,但一项长期研究报告称无严重运动并发症。我们描述了一名不寻常的患者,其帕金森病伴金刚烷胺所致的低头综合征(DHS)。该患者仅服用两种抗帕金森病药物时即出现DHS,再次使用金刚烷胺后,DHS复发,同时表面肌电图显示颈部肌肉肌张力增加。停用金刚烷胺后,DHS症状缓解。此外,静脉输注左旋多巴并未改变DHS症状。这些发现共同表明,我们这位患者的DHS很可能是由金刚烷胺直接引起的。我们的研究结果提示,金刚烷胺可能存在加重人类肌张力障碍综合征的风险。